Case Study: Fimlab achieves faster, more efficient breast cancer diagnostics with Aiforia® Breast Cancer Suite

Fimlab cuts breast cancer analysis time by up to 54% with Aiforia

Fimlab, a leading medical laboratory service provider in Finland, faced the challenge of managing high diagnostic volumes, including approximately 2,100 annual breast biopsy cases, while needing to integrate precise AI support without disrupting pathologists' workflows. To scale their digital pathology operations and avoid vendor lock-in, they turned to a solution involving Aiforia.

Aiforia implemented its CE-IVD marked Aiforia® Breast Cancer Suite, which was seamlessly integrated into Fimlab's ecosystem with partners Philips and Softwarepoint using HL7/FHIR standards. The AI models provided decision support for grading and biomarker analysis, which reduced time spent on biomarker analyses like Ki67 by up to 54%. This accelerated turnaround times, eliminated double-data entry, and gave pathologists an automated second opinion, significantly optimizing clinical efficiency.

Fimlab